Raziel Therapeutics Overview
- Founded
-
2012
- Status
-
Private
- Latest Deal Type
-
Series C
- Latest Deal Amount
-
$22.1M
- Investors
-
11
Raziel Therapeutics General Information
Description
Developer of injectable drugs created for the decrease of submental fat and fat disorders such as Dercum's disease. The company offers a single injection treatment into subcutaneous fat that causes immediate fat cell death at the injection site, enabling healthcare professionals to provide patients with a significant treatment fat reduction for long time periods without any invasive procedures.
Contact Information
Website
www.raziel-therapy.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Primary Office
- 10 Prof. Menachem Plaut Street
- Rehovot
- Israel
+972 00-000-0000
Raziel Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Later Stage VC (Series C) | 18-Dec-2019 | $22.1M | 000.00 | 0000 | Completed | Clinical Trials - Phase 2 |
| 4. Early Stage VC (Series A) | 25-Feb-2016 | 00.00 | 00.000 | 000.00 | Completed | Clinical Trials - Phase 1 |
| 3. Early Stage VC | 10-Jul-2015 | 00.00 | 00.000 | 00.000 | Completed | Clinical Trials - Phase 1 |
| 2. Seed Round | 01-Dec-2014 | $600K | $1.19M | Completed | Clinical Trials - Phase 1 | |
| 1. Early Stage VC | 03-Dec-2012 | $589K | $589K | 00.000 | Completed | Clinical Trials - Phase 1 |
Raziel Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Preferred C | 000,000 | 000.00 | 000.00 | 00 | 000.00 | 000 | ||
| Preferred B2 | 00,000 | 0000.00 | 0000.00 | 00 | 0000.00 | 0.000 | ||
| Preferred B1 | 00,000 | 0000.00 | 0000.00 | 00 | 0000.00 | 0.000 | ||
| Preferred A2 | 00,000 | 000.00 | 000.00 | 00 | 000.00 | 0.000 | ||
| Preferred A1 | 25,000 | $16.67 | $16.67 | 1x | $16.67 | 2.61% | ||
| Preferred A | 75,000 | $7.59 | $7.59 | 1x | $7.59 | 3.91% |
Raziel Therapeutics Patents
Raziel Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2021213469-A1 | Compositions for the treatment of angiolipoma | Pending | 28-Jan-2020 | 000000000 | |
| AU-2020347539-A1 | Compositions for the treatment of solid tumors | Pending | 15-Sep-2019 | 0000000000 | |
| EP-4031130-A1 | Compositions for the treatment of solid tumors | Pending | 15-Sep-2019 | 0000000000 | |
| US-20220323411-A1 | Compositions for the treatment of solid tumors | Pending | 15-Sep-2019 | 0000000000 | |
| US-20220117935-A1 | Carbazole derivatives for the treatment of fibrotic diseases and related symptoms, and conditions thereof | Pending | 15-Jun-2015 | A61K31/403 |
Raziel Therapeutics Executive Team (6)
Raziel Therapeutics Board Members (8)
| Name | Representing | Role | Since |
|---|---|---|---|
| Adi Goldin | Self | Board Member | 000 0000 |
| Alon Bloomenfeld | Raziel Therapeutics | Co-Founder, Chief Executive Officer & Board Member | 000 0000 |
| Eyal Lifschitz | Peregrine Ventures | Board Member | 000 0000 |
| Philippe Schaison Ph.D | Self | Chairman | 000 0000 |
| Shmuel Cabilly Ph.D | Self | Board Member | 000 0000 |
Raziel Therapeutics Investors (11)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| Catalyst Investments | Growth/Expansion | Minority | 000 0000 | 000000 0 | |
| China Everbright | Asset Manager | Minority | 000 0000 | 000000 0 | |
| Peregrine Ventures | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Quark Venture | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Wille Finance | Family Office | Minority | 000 0000 | 000000 0 |